A large retrospective study that analyzed 231,684 patients diagnosed with BM and newly diagnosed breast cancer showed 9.4 % of cases were HR-positive and HER2-positive, and 4.1 % were HR-negative and HER2-positive. This evidence concerns the gene ERBB2 and breast carcinoma.